Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis

• Published in: Scientific reports Vol. 14; no. 1; p. 178
• Main Authors: Peng, Yun, Wu, Yuanhui, Chen, Shiju, Liu, Yuan, Qian, Hongyan, He, Yan, Huang, Heqing, Cai, Meimei, Liu, Wen, Shi, Guixiu
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02.01.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4023; 692/53; 692/699; Anti-inflammatory agents; Arthritis; Biomarkers; Cell death; Deoxyribonucleic acid; Diagnosis; DNA; Humanities and Social Sciences; Inflammation; Inflammatory diseases; Leukocytes (neutrophilic); multidisciplinary; Nonsteroidal anti-inflammatory drugs; Rheumatic diseases; Science; Science (multidisciplinary)
• DOI: 10.1038/s41598-023-50543-0
• ISSN: 2045-2322

Microdamage and its related inflammation contribute to the development of radiographic axial spondyloarthritis (r-axSpA). Inflammation and cell death in damaged tissues are associated with cell-free DNA (cfDNA) release. Here we investigated whether circulating cfDNA could be a potential biomarker for evaluating disease activity and treatment response in r-axSpA. Circulating cfDNA was detected in the discovery and validation cohort with 79 and 60 newly diagnosed r-axSpA patients respectively and 42 healthy controls using the Quant-iT PicoGreen dsDNA reagent and kit. As a result, cfDNA levels were significantly higher in r-axSpA patients compared with healthy controls in the discovery and validation cohort. Moreover, cfDNA levels were positively correlated with CRP, ASDAS-CRP and neutrophil counts. Additionally, non-steroid anti-inflammatory drugs (NSAIDs) combined with disease-modifying anti-rheumatic drugs or tumor necrosis factor inhibitors but not NSAIDs alone could reduce cfDNA levels. Moreover, a decrease of cfDNA levels after treatment was associated with an effective therapeutic response. Intriguingly, patients with higher levels of cfDNA at diagnosis responded better to combination therapy rather than NSAIDs. However, patients with lower levels of cfDNA displayed similar responses to combination or mono-NSAID treatment. In conclusion, circulating cfDNA levels showed a significant correlation with disease activity as well as treatment efficacy in patients with r-axSpA. Moreover, cfDNA at diagnosis might predict the response to different therapy. Consequently, cfDNA may serve as a useful biomarker of inflammation in r-axSpA.